retatrutide phase 3 trial Eli Lilly obesity results 2026 Retatrutide produces up to 30.3%
Description
+ 4 mm to 8 mm covers almost all adults
Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes
When you remove effective therapy for a chronic disease, the biology of that disease has room to reassert itself
Free from stimulants or harsh chemicals
One of the first reports offering real-world data on GLP-1 efficacy found that people using the medicines had lost an average of about 1.4% of their starting body weight after three months, which steadily increased to an average of about 3% weight loss after a full year on the treatment
